Kala’s Dry Eye Treatment Meets Primary and Secondary Endpoints in Phase 3 Trial
Darrell E. White, MD
Kala's announcement of success with STRIDE 3, essentially replicating the positive results found in STRIDE 1 and STRIDE 2, is expected to solidify her bid for Eysuvis approval by the FDA later this year. As stated in…